Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

This isn't the first round of tit-for-tat actions between China and the U.S. This time, around, analysts said, China is much ...

A large research team led by nanotechnologist Roy van der Meel rebuilt the body's own proteins and fats into nano-delivery ...

AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two treatments offset continuing falling sales of its ...

AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to ...

Following two shutout losses to the New Jersey Devils (5-0) and New York Islanders (3-0), the Philadelphia Flyers have made a big move. The Flyers acquired forwards Andrei Kuzmenko and Jakob ...

Analyst Justin Zelin of BTIG maintained a Buy rating on Legend Biotech (LEGN – Research Report), retaining the price target of $91.00. Justin Zelin has given his Buy rating due to a combination ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve repair implant and FDA clearances for two over-the-counter blood sugar ...